InterX
InterX, led by Nobel Prize-winning scientists, is developing tools for pharmaceutical ligand design, material science, and biochemistry. We leverage our proprietary software tools for internal molecule development work, as well as joint ventures. Over 80% of our staff are PhDs with academic and industry experience.
Company details
Find locations served, office locations
- Business Type:
- Software vendor
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
- Year Founded:
- 2014
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
LAB DIVISION
The InterX Lab Division is applying computational and structural techniques to understanding critical biological problems. Through understanding, we gain insights and control over these processes. Our current focus is on developing new therapies for combating cancer by leveraging our in-depth knowledge of transcriptional regulation with the novel computational and structural methods developed in InterX.
DEVELOPMENT DIVISION
InterX Development Division focuses on bridging the risk gap in Drug Discovery from drug targets to novel candidates. The Development Division applies InterX’s proprietary computer-aided drug design platform, while developing collaborations with Research Centers, Pharma companies, Start-ups, Academia and Accelerators. Such collaborations help distill the drug discovery process – from target identification to lead optimization.